Alana Harris Dent

Array ( [id] => 16584102 [patent_doc_number] => 20210018504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => SHON AS A PROGNOSTIC BIOMARKER FOR CANCER AND AS A PREDICTOR OF RESPONSE TO ENDOCRINE THERAPY [patent_app_type] => utility [patent_app_number] => 16/727777 [patent_app_country] => US [patent_app_date] => 2019-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28339 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16727777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16584102 [patent_doc_number] => 20210018504 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-21 [patent_title] => SHON AS A PROGNOSTIC BIOMARKER FOR CANCER AND AS A PREDICTOR OF RESPONSE TO ENDOCRINE THERAPY [patent_app_type] => utility [patent_app_number] => 16/727777 [patent_app_country] => US [patent_app_date] => 2019-12-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28339 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16727777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399661 [patent_doc_number] => 20220041751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => COMBINATION THERAPY FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/416227 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14562 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17416227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17399661 [patent_doc_number] => 20220041751 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => COMBINATION THERAPY FOR THE TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 17/416227 [patent_app_country] => US [patent_app_date] => 2019-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14562 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -52 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17416227 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17415206 [patent_doc_number] => 20220050110 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => USE OF MCM5 AS A MARKER IN SEMEN FOR PROSTATE CANCER [patent_app_type] => utility [patent_app_number] => 17/413878 [patent_app_country] => US [patent_app_date] => 2019-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17413878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17370009 [patent_doc_number] => 20220025061 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-27 [patent_title] => COMBINATION THERAPIES FOR TREATING DISEASE USING AN INNATE IMMUNITY MODIFIER AND AN OX40 AGONIST [patent_app_type] => utility [patent_app_number] => 17/311770 [patent_app_country] => US [patent_app_date] => 2019-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21944 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -54 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17311770 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17532457 [patent_doc_number] => 20220111066 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-14 [patent_title] => ANTIBODY-DRUG CONJUGATE WITH IMPROVED THERAPEUTIC WINDOW [patent_app_type] => utility [patent_app_number] => 17/312403 [patent_app_country] => US [patent_app_date] => 2019-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63728 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17312403 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595365 [patent_doc_number] => 20220144938 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => IDENTIFICATION AND TARGETING OF TUMOR PROMOTING CARCINOMA ASSOCIATED FIBROBLASTS FOR DIAGNOSIS AND TREATMENT OF CANCER AND OTHER DISEASES [patent_app_type] => utility [patent_app_number] => 17/299265 [patent_app_country] => US [patent_app_date] => 2019-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36819 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17299265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15866327 [patent_doc_number] => 20200140567 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-07 [patent_title] => IMMUNOGENIC MODULATION BY ENDOCRINE DEPRIVATION THERAPY IMPROVES SENSITIVITY OF TUMOR CELLS TO IMMUNE MEDIATED LYSIS [patent_app_type] => utility [patent_app_number] => 16/686390 [patent_app_country] => US [patent_app_date] => 2019-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10419 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16686390 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314518 [patent_doc_number] => 20210403566 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => IMMUNOGENIC ARGINASE 2 POLYPEPTIDES [patent_app_type] => utility [patent_app_number] => 17/293325 [patent_app_country] => US [patent_app_date] => 2019-11-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15823 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17293325 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15524847 [patent_doc_number] => 20200054729 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => NOVEL PEPTIDES, COMBINATION OF PEPTIDES AND SCAFFOLDS FOR USE IN IMMUNOTHERAPEUTIC TREATMENT OF VARIOUS CANCERS [patent_app_type] => utility [patent_app_number] => 16/673619 [patent_app_country] => US [patent_app_date] => 2019-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68160 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 125 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16673619 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15493259 [patent_doc_number] => 20200046818 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => YEAST-BASED IMMUNOTHERAPY FOR CHORDOMA [patent_app_type] => utility [patent_app_number] => 16/664543 [patent_app_country] => US [patent_app_date] => 2019-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30209 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16664543 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15768871 [patent_doc_number] => 20200115453 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-04-16 [patent_title] => Anti-CD28 Humanized Antibodies Formulated for Administration to Humans [patent_app_type] => utility [patent_app_number] => 16/662399 [patent_app_country] => US [patent_app_date] => 2019-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16128 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16662399 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15529529 [patent_doc_number] => 20200057070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => DIAGNOSTIC METHODS FOR LIVER DISORDERS [patent_app_type] => utility [patent_app_number] => 16/653268 [patent_app_country] => US [patent_app_date] => 2019-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8845 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16653268 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460333 [patent_doc_number] => 20220073638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCERS RESISTANT TO IMMUNE CHECKPOINT THERAPY [patent_app_type] => utility [patent_app_number] => 17/276432 [patent_app_country] => US [patent_app_date] => 2019-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20148 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17276432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17460333 [patent_doc_number] => 20220073638 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-10 [patent_title] => METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCERS RESISTANT TO IMMUNE CHECKPOINT THERAPY [patent_app_type] => utility [patent_app_number] => 17/276432 [patent_app_country] => US [patent_app_date] => 2019-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20148 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17276432 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16042957 [patent_doc_number] => 10683337 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-06-16 [patent_title] => Peptides, combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers [patent_app_type] => utility [patent_app_number] => 16/563704 [patent_app_country] => US [patent_app_date] => 2019-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 14 [patent_no_of_words] => 35707 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16563704 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15345275 [patent_doc_number] => 20200010529 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => NOVEL PEPTIDES, COMBINATION OF PEPTIDES AS TARGETS AND FOR USE IN IMMUNOTHERAPY AGAINST GALLBLADDER CANCER AND CHOLANGIOCARCINOMA AND OTHER CANCERS [patent_app_type] => utility [patent_app_number] => 16/563740 [patent_app_country] => US [patent_app_date] => 2019-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35820 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16563740 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17443775 [patent_doc_number] => 20220064280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-03 [patent_title] => METHODS OF TREATING PSORIASIS [patent_app_type] => utility [patent_app_number] => 17/275027 [patent_app_country] => US [patent_app_date] => 2019-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14107 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17275027 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15268239 [patent_doc_number] => 20190382853 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => MEST AS BIOMARKER FOR CANCER DIAGNOSIS AND PROGNOSIS AND METHOD FOR USING THEREOF [patent_app_type] => utility [patent_app_number] => 16/558455 [patent_app_country] => US [patent_app_date] => 2019-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8353 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 200 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16558455 [rel_patent_id] =>[rel_patent_doc_number] =>)